These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30216418)

  • 1. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
    Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
    Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to imatinib plus sirolimus in advanced chordoma.
    Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
    Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib in advanced chordoma: A retrospective case series analysis.
    Hindi N; Casali PG; Morosi C; Messina A; Palassini E; Pilotti S; Tamborini E; Radaelli S; Gronchi A; Stacchiotti S
    Eur J Cancer; 2015 Nov; 51(17):2609-14. PubMed ID: 26283036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study on lapatinib in advanced EGFR-positive chordoma.
    Stacchiotti S; Tamborini E; Lo Vullo S; Bozzi F; Messina A; Morosi C; Casale A; Crippa F; Conca E; Negri T; Palassini E; Marrari A; Palmerini E; Mariani L; Gronchi A; Pilotti S; Casali PG
    Ann Oncol; 2013 Jul; 24(7):1931-1936. PubMed ID: 23559153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
    Lebellec L; Chauffert B; Blay JY; Le Cesne A; Chevreau C; Bompas E; Bertucci F; Cupissol D; Fabbro M; Saada-Bouzid E; Duffaud F; Feuvret L; Bonneville-Levard A; Bay JO; Vauleon E; Vinceneux A; Noel G; Penel N; Mir O
    Eur J Cancer; 2017 Jul; 79():119-128. PubMed ID: 28478340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of imatinib in advanced chordoma.
    Stacchiotti S; Longhi A; Ferraresi V; Grignani G; Comandone A; Stupp R; Bertuzzi A; Tamborini E; Pilotti S; Messina A; Spreafico C; Gronchi A; Amore P; Vinaccia V; Casali PG
    J Clin Oncol; 2012 Mar; 30(9):914-20. PubMed ID: 22331945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
    ElNaggar AC; Hays JL; Chen JL
    PLoS One; 2016; 11(6):e0156985. PubMed ID: 27295141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network.
    Baldi GG; Lo Vullo S; Grignani G; Vincenzi B; Badalamenti G; Mastore M; Buonomenna C; Morosi C; Barisella M; Frezza AM; Provenzano S; Simeone N; Picozzi F; Mariani L; Casali PG; Stacchiotti S
    Cancer; 2022 Apr; 128(7):1439-1448. PubMed ID: 35026050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.
    Schuetze SM; Bolejack V; Choy E; Ganjoo KN; Staddon AP; Chow WA; Tawbi HA; Samuels BL; Patel SR; von Mehren M; D'Amato G; Leu KM; Loeb DM; Forscher CA; Milhem MM; Rushing DA; Lucas DR; Chugh R; Reinke DK; Baker LH
    Cancer; 2017 Jan; 123(1):90-97. PubMed ID: 27696380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
    Buzzoni R; Pusceddu S; Bajetta E; De Braud F; Platania M; Iannacone C; Cantore M; Mambrini A; Bertolini A; Alabiso O; Ciarlo A; Turco C; Mazzaferro V
    Ann Oncol; 2014 Aug; 25(8):1597-603. PubMed ID: 24827133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.
    Stacchiotti S; Simeone N; Lo Vullo S; Morosi C; Greco FG; Gronchi A; Barisella M; Collini P; Zaffaroni N; Dagrada GP; Frezza AM; Mariani L; Casali PG
    Eur J Cancer; 2019 Jan; 106():225-233. PubMed ID: 30528807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
    Liu C; Jia Q; Wei H; Yang X; Liu T; Zhao J; Ling Y; Wang C; Yu H; Li Z; Jiao J; Wu Z; Yang C; Xiao J
    Lancet Oncol; 2020 Sep; 21(9):1244-1252. PubMed ID: 32888455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
    Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
    J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
    Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
    Adenis A; Ray-Coquard I; Italiano A; Chauzit E; Bui-Nguyen B; Blay JY; Tresch-Bruneel E; Fournier C; Clisant S; Amela EY; Cassier PA; Molimard M; Penel N
    Br J Cancer; 2013 Nov; 109(10):2574-8. PubMed ID: 24149182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chordoma: a case series and review of the literature.
    Alan O; Akin Telli T; Ercelep O; Tanrikulu Simsek E; Basoglu Tuylu T; Mutis A; Hasanov R; Kaya S; Akgül Babacan N; Dane F; Yumuk PF
    J Med Case Rep; 2018 Aug; 12(1):239. PubMed ID: 30145982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
    Schneider TC; de Wit D; Links TP; van Erp NP; van der Hoeven JJ; Gelderblom H; Roozen IC; Bos M; Corver WE; van Wezel T; Smit JW; Morreau H; Guchelaar HJ; Kapiteijn E
    J Clin Endocrinol Metab; 2017 Feb; 102(2):698-707. PubMed ID: 27870581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
    Maurel J; Martins AS; Poveda A; López-Guerrero JA; Cubedo R; Casado A; Martínez-Trufero J; Ramón Ayuso J; Lopez-Pousa A; Garcia-Albeniz X; Garcia del Muro X; de Alava E
    Cancer; 2010 Aug; 116(15):3692-701. PubMed ID: 20564079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
    Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
    Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.